Safety and Effectiveness of Drop-free Small Incision Cataract Surgery

Cataract Clinical Trial

Official title:

Safety and Effectiveness of Single-dose Subconjunctival Triamcinolone Compared to Topical Prednisolone Eye Drops in Manual Small Incision Cataract Surgery

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05248139
• Other study ID #: Dropfree MSICS
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 2022
• Est. completion date: February 2023

Study information

• Verified date: August 2022
• Source: Visualiza
• Contact: Lucia Silva, MD
• Phone: 50224140880
• Email: Lucia.Silva[@]visualiza.org.gt
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized control trial comparing the effects of subconjunctival triamcinolone administration during surgery to topical prednisolone drops on the development of post-operative inflammation and macular edema in manual small incision cataract surgery.

Description:

Eye drops given following cataract surgery for prevention of post-operative inflammation carry many disadvantages, such as cost and poor medication adherence. To eliminate these barriers, the emerging technique of single dose of subconjunctival triamcinolone delivered during surgery has been shown an effective and safe alternative. The goal of this study is to build on this evidence, utilizing subconjunctival triamcinolone in conjunction with a different surgical technique and population as what was previously studied. This is a randomized control trial comparing the effects of single-dose subconjunctival triamcinolone administration at the time of surgery to the standard 4-week taper of topical prednisolone drops following manual small incision cataract surgery in Guatemala. Patients will be evaluated at post-operative weeks 6 and 12 with the primary outcome variables of intraocular pressure and best corrected visual acuity. Data on presence and amount of corneal edema, anterior chamber inflammation, and development of macular edema will also be obtained.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: February 2023
• Est. primary completion date: February 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

• Presence of a visually significant cataract: nuclear sclerotic, posterior subcapsular and/or cortical

• Best corrected visual acuity or 20/40 or worse

Exclusion Criteria:

• Axial length < 20 or > 26 mm

• Cataract which is traumatic, subluxated, or Morgagnian

• Presence of ocular comorbidity: including corneal or retinal abnormalities (corneal opacities, macular degeneration, macular scars, epiretinal membrane, retinal detachment, retinal vascular occlusion), glaucoma, ocular hypertension, glaucoma suspect (cup-to-disc ratio of 0.7 or more, history of steroid response, history of uveitis, pseudoexfoliation

• History of endophthalmitis or macular edema in the fellow eye

• Personal history of diabetes mellitus or uncontrolled hypertension

• Currently pregnant or lactating women

• Current use of systemic steroids for asthma, rheumatoid arthritis or other illness or history of steroid use by any route in the prior 3 months.

• Intraoperative complications including posterior capsular rupture, iris prolapse, zonular dialysis, retained nucleus, vitreous loss, iris trauma resulting in hemorrhage, Descemet dehiscence of more than 1 mm x 1 mm

Related Conditions & MeSH terms

• Cataract
• Inflammation
• Ocular Hypertension
• Ocular Inflammation
• Post-Op Complication
• Postoperative Complications

Intervention

Drug:
• Intraoperative delivery of medication, Kenalog (Triamcinolone)
Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
• Topical post-operative eyedrops, Prednisolone acetate
Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Visualiza	Seva Foundation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean post-operative intraocular pressure (IOP) in mmHg in each group	Comparison of mean IOP in mmHg obtained by applanation between control and intervention groups at all time points	Pre-operative exam through post-operative month week 12
Primary	Corrected distance visual acuity (CDVA)	Comparison of visual acuity following refraction quantified on a the logarithm of the minimum angle of resolution (LogMAR) scale with a range from -0.30 (Snellen equivalent 6/3) with exceptional vision to +3.00 which corresponds to poor vision or only able to discriminate hand motions.	Pre-operative exam through post-operative week 12
Secondary	Degree of inflammation using anterior chamber (AC) inflammation score	Comparison between groups; score obtained by slit lamp examination by a single, non-operating investigational surgeon at all clinic time points. Patients will receive a number for anterior chamber cell ranging from 0 which equals no inflammatory cells visible to 4, or >50 visible cells in the anterior chamber according to the Standardization of Uveitis Nomenclature (SUN) scoring system. This will then be added to the patient's flare score ranging from 0, or no flare, to 4+, which signifies high levels of inflammation, such as fixed or plastic anterior chamber fluid. The summation of these values will determine the patient's overall anterior inflammation score for that examination date.	Pre-operative exam through post-operative week 12
Secondary	Incidence of treatment-emergent macular edema	Incidence of macular edema compared between treatment groups. Macular edema defined as BCVA of 20/40 or worse and ocular coherence tomography with identifiable cystoid spaces within the macula (central 1 mm) or central subfield thickening of 320 µm or greater.	Post-operative month one through post-operative week 12